Photo of Boris Gershman,  MD

Boris Gershman, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-3739


bgershma@bidmc.harvard.edu

Boris Gershman, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor, Surgery, Harvard Medical School
  • Urologist, Surgery, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research interests focus on two overarching areas. First, I am interested in investigating the comparative effectiveness of treatments for urologic cancers. Although randomized clinical trials are the preferred study design to evaluate the comparative effectiveness of interventions, there are very few trials comparing surgical treatments within urologic oncology, in part due to the difficulty of conducting surgical trials. To address such fundamental evidence gaps, I am interested in the application of two novel observational research methods when clinical trial evidence is limited: emulation of target clinical trials using observational datasets, and transportation of inferences from competed clinical trials to “real-world” patient populations.

My other research interest is the development of deep learning methods to improve the diagnosis and risk-stratification of urologic cancers. Together with collaborators from Brown University, we have developed deep learning methods to improve the histopathologic diagnosis and Gleason grading of prostate cancer biopsy specimens. Additional work is ongoing to extend these efforts to other prediction tasks.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Liu Y, Zhao YC, Lu Y, Goodarz D, Gershman B. The role of smoking in explaining racial/ethnic disparities in bladder cancer incidence in the United States. Urol Oncol 2023. PubMed
  • Morton E, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim SP, Bellmunt J, Kaplan I, Olumi AF, Gershman B. Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection. Urol Oncol 2022. PubMed
  • Estevez A, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Bellmunt J, Olumi AF, Rayala H, Gershman B. Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer. Urol Oncol 2022. PubMed
  • Schaufler C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim S, Bellmunt J, Kaplan I, Olumi AF, Gershman B. Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis 2022. PubMed
  • Rodriguez-Homs M, Pessoa RR, Konety B, Gershman B, Clark PE, Bronsert M, Flaig TW, Tevis SE, Lloyd G, Morrison JC, Kim SP. Association of Surgical Approach and Urinary Diversion in Radical Cystectomy for Bladder Cancer With Costs and Readmission: Results From a Large Private Health Insurance Cohort. Urol Pract 2022; 9:551-558. PubMed
  • Ramos F, Korets R, Fleishman A, Kaul S, Johnson M, Wei JL, Olumi AF, Tsai LL, Gershman B. Comparative Effectiveness of Magnetic Resonance Imaging-Ultrasound Fusion Versus In-bore Magnetic Resonance Imaging-targeted Prostate Biopsy. Urology 2022. PubMed
  • Morrison JC, Sax-Bolder A, Gershman B, Konety B, Clark PE, Gonzalez CM, Bronsert MR, Lloyd G, Pessoa RR, Ballon-Landa E, Kim SP. Geographic Variation of Infectious Complications Following Prostate Biopsy in The United States: Results From a Population-Based Cohort of Privately Insured Patients. Urology 2022. PubMed
  • Bharadwaj M, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim S, Bellmunt J, Kaplan I, Olumi AF, Gershman B. Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder. Urol Oncol 2022. PubMed
  • Softness K, Kaul S, Fleishman A, Efstathiou J, Bellmunt J, Kim SP, Korets R, Chang P, Wagner A, Olumi AF, Gershman B. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol Oncol 2022. PubMed
  • Moshnikova A, Golijanin B, Amin A, Doyle J, Kott O, Gershman B, DuPont M, Li Y, Lu X, Engelman DM, Andreev OA, Reshetnyak YK, Golijanin D. Targeting Bladder Urothelial Carcinoma with pHLIP-ICG and Inhibition of Urothelial Cancer Cell Proliferation by pHLIP-amanitin. Front Urol 2022. PubMed
  • Sharkey C, Long X, Wang Z, Al-Faouri R, Gershman B, Tsai LL, Olumi AF. Zonal Growth Pattern of the Prostate Is Affected by Age and Body Mass Index. J Urol 2022; 207:876-884. PubMed
  • Liu S, Wang Z, Long X, Fleishman A, Huang X, Wu Q, Gershman B, Olumi AF. Single black men have the worst prognosis with localized prostate cancer. Can J Urol 2022; 29:10992-11002. PubMed
  • Cahill LC, Rosen S, Yoshitake T, Wu Y, York L, Tsai LL, Gershman B, Fujimoto JG, Sun Y. Real-time diagnosis and Gleason grading of prostate core needle biopsies using nonlinear microscopy. Mod Pathol 2021. PubMed
  • Nathan A, Gershman B, Van der Poel H, Sooriakumaran P. Centralisation of Care for Prevalent Urological Malignancies: The Case for Prostate Cancer. Eur Urol Focus 2021; 7:920-923. PubMed
  • Monfared S, Fleishman A, Korets R, Chang P, Wagner A, Bubley G, Kaplan I, Olumi AF, Gershman B. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance. Urol Oncol 2021. PubMed
  • Reitblat C, Fleishman A, Kaplan IA, Stensland KD, D'Amico AV, Olumi AF, Wagner AA, Chang PK, Kim SP, Korets R, Gershman B. Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. Urol Oncol 2021. PubMed
  • Rodrigues Pessoa R, Mueller AC, Boxley P, Flaig TW, Piper C, Konety B, Yu JB, Gershman B, Kukreja J, Kim SP. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. Urol Oncol 2021. PubMed
  • Rodrigues Pessoa R, Morrison JC, Konety B, Gershman B, Maroni P, Kukreja JB, Cost N, Flaig T, Kessler E, Sharma P, Kim SP. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urol Oncol 2021. PubMed
  • Shantharam G, Amin A, Pereira J, Kott O, Mueller-Leonhard C, Mega A, Golijanin D, Gershman B. Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure. Curr Urol 2021; 15:33-38. PubMed
  • Unadkat P, Fleishman A, Olumi AF, Wagner A, Chang P, Kim SP, Korets R, Gershman B. Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men with Clinically Node-Negative (cN0) Penile Cancer. Urology 2021. PubMed
  • Reitblat C, Bellmunt J, Gershman B. Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder. Curr Oncol Rep 2021; 23:24. PubMed
  • Chandrasekar T, Boorjian SA, Capitanio U, Gershman B, Mir MC, Kutikov A. Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. Eur Urol 2021. PubMed
  • Reitblat C, Bain PA, Porter ME, Bernstein DN, Feeley TW, Graefen M, Iyer S, Resnick MJ, Stimson CJ, Trinh QD, Gershman B. Value-Based Healthcare in Urology: A Collaborative Review. Eur Urol 2021. PubMed
  • Golijanin B, Gershman B, De Souza A, Kott O, Carneiro BA, Mega A, Golijanin DJ, Amin A. p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma. 2021; 11:651754. PubMed
  • Puneet K, Tilburt JC, Volk RJ, Bennett CL, Qureshi Z, Gershman B, Sedlacek HM, Kim SP. Do radiation oncologists and urologists endorse decision aids for active surveillance of low-risk prostate cancer: Results from a national survey. Eur J Cancer Care (Engl) 2021; 30:e13301. PubMed
  • Morrison JC, Gershman B, Konety B, Cost N, Kim SP. Centralization of Health Care to Facilitate Greater Use of Nephron-Sparing Surgery for Localized Renal Tumors: Identifying Appropriate Health Care Delivery. Ann Surg Oncol 2020; 27:1735-1736. PubMed
Hide
Member Summary Video